Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

Breast Cancer Research and Treatment

Volumn 77, Issue 2, 2003, Pages 109-114

  Watters, A D ^a   Going, J J ^a   Cooke, T G ^a   Bartlett, J M S ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; Chromosome 17; FISH; HER2 neu

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CANCER TISSUE; CHROMOSOME 17; CHROMOSOME 17 ANEUSOMY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME SATELLITE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; DNA PROBES; FEMALE; GENE DOSAGE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PROGNOSIS;

EID: 0037272682     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021399923825     Document Type: Article

References (21)

1. Pinder SE, Ellis IO, Elston CW: Prognostic factors in primary breast carcinoma. J Clin Pathol 48: 981-983, 1995
2. Written on behalf of the Biomarkers Ad-hoc Group of the United Kingdom Coordinating Committee on Cancer Research: Can biological markers improve the management of breast cancer patients? Br J Cancer 82: 1625-1626, 2000
3. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63-72, 1996
4. Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R: Assessment of HER2 status in breast cancer: why when and how? Eur J Cancer 36: 170-176, 2000
5. McManus DT, Patterson AH, Maxwell P, Hamilton PW, Anderson NH, Caughley LM, Toner PG: Interphase cytogenetics of chromosomes 11 and 17 in fine needle aspirates of breast cancer. Hum Pathol 30: 137-144, 1999
6. Sigurdsson S, Bödvarsdottir SK, Anamthawat-Jonsson K, Steinarsdottir M, Jonasson JG, Ögmundsdottir HM, Eyfjörd JE: p53 abnormality and chromosomal instability in the same breast tumor cells. Cancer Genet Cytogenet 121: 150-155, 2000
7. Adeyinka A, Mertens F, Idvall I, Bondeson L, Pandis N: Multiple polysomies in breast carcinomas: preferential gain of chromosomes 1, 5, 6, 7, 12, 16, 17, 18, and 19. Cancer Genet Cytogenet 111: 144-148, 1999
8. Herrington CS, Leek RD, McGee JO'D: Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes. J Pathol 176: 353-359, 1995
9. Ichikawa D, Hashimoto N, Hoshima M, Yamaguchi T, Sawai K, Nakamura Y, Yakahashi T, Abe T, Inazawa J: Analysis of numerical aberrations in specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer. Cancer 77: 2064-2069, 1995
10. Tsukamoto F, Miyoshi Y, Koyama H, Watatani M, Sasa M, Shiba E, Takami S, Inazawa J, Noguchi S: Detection of chromosomal aneusomy by fluorescence in situ hybridization in fine-needle aspirates from breast tumors: application to the preoperative diagnosis of breast carcinoma. Cancer Cytopathol 90: 373-378, 2000
11. Bartlett JMS, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG: Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 193: 1-7, 2001
12. Watters AD, Ballantyne SA, Going JJ, Grigor KM, Bartlett JMS: Aneusomy of chromosomes 7 and 17 predicts recurrence of transitional cell carcinoma of the urinary bladder. Br J Urol 85: 42-47, 2000
13. Bartlett JMS, Watters AD, Ballantyne SA, Going JJ, Grigor KM, Cooke TG: Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Br J Cancer 77: 2193-2198, 1998
14. Reeves JR, Going JJ, Smith G, Cooke TG, Ozanne BW, Stanton PD: Quantitative radioimmunohistochemical measurements of p185 (erbB-2) in frozen tissue sections. J Histochem Cytochem 44: 1251-1259, 1996
15. Phelan CM, Borg A, Cuny M, Crichton DN, Baldersso T, Ikdahl T, Maria A, Caligo A, Lidereau R, Lindblom A, Seit S, Kelsell D, Hamann U, Rio P, Thorlacius S, Papp J, Olah E, Ponder B, Bignon Y, Scherneck S, Barkardottir R, Borresen-Dale A, Eyfjord J, Theillet C, Thompson AM, Devilee P, Larsson C: Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res 58: 1004-1012, 1998
16. Botti C, Pescatore B, Mottolese M, Sciarretta F, Greco C, Di Filippo F, Gandolfo GM, Cavaliere F, Bovani R, Varanese A, Cianciulli AM: Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study. J Am Coll Surg 190: 516-525, 2000
17. Micale MA, Visscher DW, Gulino SE, Wolman SR: Chromosomal aneuploidy in proliferative breast disease. Hum Pathol 25: 29-35, 1994
18. Wolman SR: Fluorescence in situ hybridization: a new tool for the pathologist. Hum Pathol 25: 586-590, 1994
19. Ried T, Heselmeyer-Haddad K, Blegen H, Schrock E, Auer G: Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromos Cancer 25: 195-204, 1999
20. Dillon DA, Howe CL, Bosari S, Costa J: The molecular biology of breast cancer: accelerating clinical applications. Crit Rev Oncogen 9: 125-140, 1998
21. Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kaye SB, Brown R, Keith WN: Interphase cytogenetic analysis of erbB2 and topoIIalpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 64: 18-26, 1995